Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

including AZ’s own Iressa (gefitinib) and Roche’s Tarceva (erlotinib).

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status This type of mutation occurs in tumours that aren’t sensitive to treatment with first- and second-generation small-molecule EGFR inhibitors like AstraZeneca’s Iressa (gefitinib), Roche’s Tarceva (erlotinib)

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC That study evaluated Cyramza alongside Roche’s Tarceva (erlotinib), where it demonstrated media progression-free survival of 19.4 months, compared to 12.4 months in the placebo-plus-Tarceva arm. ... Tarceva “is associated with increased toxicity

Tagrisso tops rival drugs on survival in first-line lung cancer

Tagrisso tops rival drugs on survival in first-line lung cancer The improvement in OS came over other drugs in the EGFR inhibitor class, namely AZ’s own Iressa (gefitinib) and Roche’s Tarceva (erlotinib), and according to AZ’s head of

AstraZenca to appeal NICE rejection of Tagrisso

AstraZenca to appeal NICE rejection of Tagrisso NICE agreed that Tagrisso extends progression-free (PFS) and overall survival (OS) compared with first generation EGFR-targeting drugs Iressa and Tarceva, but said the size of the benefit is unclear.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genetic Digital

Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...